Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | WNT5A |
| Gene Name: | WNT5A |
| Protein Full Name: | Protein Wnt-5a |
| Mass (Da): | 42339 |
| Number AA: | 380 |
| UniProt ID: | P41221 |
| Locus ID: | 7474 |
| COSMIC ID: | WNT5A |
| Gene location on chromosome: | 3p14.3 |
| Cancer protein type: | MIXED |
| Effect of cancer mutation on protein: | UNCLEAR (no mutations recorded) |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20057 |
| Percent of cancer specimens with mutations: | 0.39 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | WNT5A is a ligand for members of the frizzled family of GPCRs. It can both activate or inhibit Wnt signalling via FZD4 or ROR2, respectively, depending on the receptor. The Wnt pathway plays a role in proliferation, migration, and cell motility, and WNT5A may promote or inhibit any of these processes. In general, however, it appears to decrease proliferation, migration, and invasiveness of carcinoma cells, acting as a tumour suppressor. It may also be involved in the suppression of angiogenesis via the Wnt pathway as well. Overexpression in melanoma, gastric cancer and osteosarcoma is associated with poor prognoses, whereas in breast cancer, colorectal cancer, and acute lymphocytic leukemia it is associated with better outcomes. |